Jupiter Neurosciences financials
$2.58+2.79%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 |
|---|---|---|---|---|---|---|---|
| Revenue | $24.2K | $18.7K | $21.8K | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $21.1K | $14.3K | $17.6K | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | 86.9% | 76.6% | 80.6% | — | — | — | — |
| Operating income | -$2.7M | -$2.0M | -$2.8M | -$2.3M | -$2.3M | -$1.5M | -$1.5M |
| Net income | -$2.3M | -$2.1M | -$2.6M | -$2.3M | -$2.3M | -$1.5M | -$1.5M |
| Net margin | −9380.9% | −11054.9% | −11814.2% | — | — | — | — |
| Diluted EPS | $-4.08 | $-4.50 | $-2.72 | $-5.25 | $-5.09 | $-3.75 | $-4.25 |
| EBITDA | -$2.6M | -$1.8M | -$2.6M | -$2.1M | -$2.1M | -$1.3M | -$1.4M |
| Operating cash flow | -$2.3M | -$1.4M | -$2.4M | -$1.2M | -$828.2K | -$1.1M | -$3.7M |
| Free cash flow | -$2.3M | -$1.4M | -$2.4M | -$1.2M | -$828.2K | -$1.1M | -$3.7M |
| Diluted shares | 0.6M | 0.5M | 0.9M | 0.5M | 0.4M | 0.4M | 0.4M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.5M | $2.4M | $3.8M | $723.8K | $1.9M | $2.7M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $1.5M | $4.8M | $5.3M | $4.3K | $3.2K | $2.1K |
| Total assets | $3.7M | $3.9M | $5.6M | $2.6M | $4.0M | $5.0M |
| Total liabilities | $4.1M | $6.7M | $7.4M | $2.5M | $2.6M | $1.9M |
| Shareholders' equity | -$366.0K | -$2.8M | -$1.8M | $57.4K | $1.3M | $3.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology